Ureaplasma urealyticum, a pathogenic bacterium within the Mycoplasmataceae family, is known for its petite size and absence of a cell wall, rendering it naturally resilient to numerous standard antibiotics, notably beta-lactams. Leveraging our wealth of expertise, our firm offers pioneering services for the development of vaccines and therapeutics targeting ureaplasma urealyticum infections.
Overview of Ureaplasma Urealyticum Infection
Ureaplasma urealyticum, a member of the Mollicutes class, is a significant pathogen that frequently resides in the urogenital tract, often asymptomatically but with the potential to cause a range of diseases, including non-gonococcal urethritis, chorioamnionitis, and neonatal respiratory diseases. The pathogen's small size, high auxotrophy, and lack of a cell wall present unique challenges in detection, therapeutics, and prevention strategies.
Fig.1 Bioinformatics analysis of DnaJ based on the amino acid sequences. (Guo F., et al., 2022)
Vaccine Development for Ureaplasma Urealyticum Infection
Recombinant Vaccines
Recombinant technology has been pivotal in developing vaccines against U. urealyticum. One such example is the DnaJ-based vaccine, which has shown promise in inducing robust humoral and cellular immune responses in preclinical models. The DnaJ protein, a heat shock protein, is highly conserved among U. urealyticum serovars, making it an attractive candidate for broad-spectrum vaccine development.
Peptide-based Vaccines
In silico methods have been employed to identify immunogenic proteins from U. urealyticum, leading to the design of peptide-based vaccines. These vaccines leverage the antigenic properties of specific proteins to elicit a targeted immune response. The approach has been successful in identifying potential vaccine candidates that are antigenic, membrane-bound, and non-allergenic.
Therapeutics Development for Ureaplasma Urealyticum Infection
Azithromycin is frequently used due to its effectiveness against Ureaplasma spp. Its role in treating intra-amniotic infections during pregnancy is particularly notable, given its favorable safety profile. In addition, doxycycline is another option, although it is less favored in pregnant women due to potential side effects. This class of antibiotics targets protein synthesis and has demonstrated efficacy against Ureaplasma species. Although effective, the emergence of resistant strains of fluoroquinolones poses a significant challenge. Continuous surveillance and susceptibility testing are essential to guide empirical therapy.
Our drug development services focus on identifying novel antimicrobial agents with potent activity against U. urealyticum. We also investigate the mechanisms of antibiotic resistance to design drugs that can overcome existing resistance patterns. Please click on the link below to find your one-stop solution.
Our Services
At our company, we pride ourselves on our comprehensive services in vaccine and therapy development for Ureaplasma urealyticum infections. Our multidisciplinary team of experts utilizes cutting-edge technologies and methodologies to advance research in this field.
Infectious Disease Models
- Murine Models of Ureaplasma urealyticum Pneumonia
- Newborn Mouse Models (CD-1 outbred mice and C3H/HeN mice)
- Primate Model of Ureaplasma urealyticum Infection in the Premature Infant with Hyaline Membrane Disease
- Novel Mouse Models of Ureaplasma-Induced Perinatal Inflammation
Preclinical research is a critical step in the development of effective vaccines and therapies. Our company offers robust preclinical research services tailored for Ureaplasma urealyticum infection. If you are interested in our services, please feel free to contact us.
References
- Guo, Fangyi, et al. "DnaJ, a promising vaccine candidate against Ureaplasma urealyticum infection." Applied Microbiology and Biotechnology 106.22 (2022): 7643-7659.
- Tantengco, Ourlad Alzeus G., and Itaru Yanagihara. "Current understanding and treatment of intra‐amniotic infection with Ureaplasma spp." Journal of Obstetrics and Gynaecology Research 45.9 (2019): 1796-1808.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
